Analysis and Insights
To predict the stock price of Calumet Specialty Products Partners (CLMT) for the next trading week, we analyze both news sentiment and technical indicators.
News Sentiment Analysis:
Analyst Upgrades and Price Targets:
- UBS upgraded CLMT from Sell to Neutral with a price target of $12, reflecting better alignment of the stock price with earnings risks and cash flow challenges.
- Goldman Sachs maintained a Buy rating but lowered the price target to $17 from $21, citing updates related to the MaxSAF expansion and Q4 earnings.
Market Sentiment:
- The stock has declined 45% year-to-date due to policy changes and market reassessment of risks.
- Recent sell-off is considered overdone by Goldman Sachs, indicating potential buying opportunities.
Technical Analysis:
Price Trends:
- Current price: $12.67 (as of 2025-03-24).
- Fibonacci levels suggest resistance at $13.28 and support at $10.68.
Technical Indicators:
- RSI (6, 12, 14): 48.28, 42.92, 41.88, indicating the stock is not in oversold territory.
- MACD: Slightly negative but showing signs of potential bullish crossover.
Volume and Price Action:
- Volume has decreased over the past few trading sessions, suggesting reduced selling pressure.
- Recent price action shows a potential reversal pattern, with the stock bouncing off the lower Fibonacci support level.
Price Prediction and Recommendation:
Based on the analysis, CLMT is expected to reach $13.20 in the next trading week. The stock is likely to test the Fibonacci resistance level at $13.28, driven by potential oversold conditions and positive analyst sentiment.
Recommendation: Buy CLMT with a target price of $13.20. Consider setting a stop-loss below $12 to manage risk.
Analysis and Insights
To predict the stock price of Calumet Specialty Products Partners (CLMT) for the next trading week, we analyze both news sentiment and technical indicators.
News Sentiment Analysis:
Analyst Upgrades and Price Targets:
- UBS upgraded CLMT from Sell to Neutral with a price target of $12, reflecting better alignment of the stock price with earnings risks and cash flow challenges.
- Goldman Sachs maintained a Buy rating but lowered the price target to $17 from $21, citing updates related to the MaxSAF expansion and Q4 earnings.
Market Sentiment:
- The stock has declined 45% year-to-date due to policy changes and market reassessment of risks.
- Recent sell-off is considered overdone by Goldman Sachs, indicating potential buying opportunities.
Technical Analysis:
Price Trends:
- Current price: $12.67 (as of 2025-03-24).
- Fibonacci levels suggest resistance at $13.28 and support at $10.68.
Technical Indicators:
- RSI (6, 12, 14): 48.28, 42.92, 41.88, indicating the stock is not in oversold territory.
- MACD: Slightly negative but showing signs of potential bullish crossover.
Volume and Price Action:
- Volume has decreased over the past few trading sessions, suggesting reduced selling pressure.
- Recent price action shows a potential reversal pattern, with the stock bouncing off the lower Fibonacci support level.
Price Prediction and Recommendation:
Based on the analysis, CLMT is expected to reach $13.20 in the next trading week. The stock is likely to test the Fibonacci resistance level at $13.28, driven by potential oversold conditions and positive analyst sentiment.
Recommendation: Buy CLMT with a target price of $13.20. Consider setting a stop-loss below $12 to manage risk.